
zzso regarding cancer risk in people with multiple sclerosis have been inconsistent and few studies have explored the possibility of diagnostic zzso The influence of a zzso versus primary progressive course on cancer risk is zzso We examined cancer risk and zzso size at diagnosis in a cohort of patients with multiple sclerosis compared to the general population and we explored the influence of disease zzso Clinical data of patients with multiple sclerosis residing in British Columbia, Canada who visited a British Columbia multiple sclerosis clinic from 1980 to 2004 were linked to provincial cancer registry, vital statistics and health registration zzso Patients were followed for incident zzso between onset of multiple zzso and the earlier of zzso death or study end zzso December zzso Cancer zzso was compared with that in the zzso zzso and calendar zzso population of British zzso zzso size at diagnosis of breast, zzso zzso and lung zzso were compared with population controls, matched for cancer site, sex, age and calendar year at cancer diagnosis, using the zzso zzso zzso There were zzso patients included, with 110 666 zzso of zzso The standardized zzso ratio for all zzso was zzso zzso confidence zzso zzso zzso cancer risk was also significantly reduced zzso zzso zzso zzso zzso confidence zzso zzso zzso reductions were similar by sex and for zzso and primary progressive multiple zzso zzso size was larger than expected in the cohort zzso zzso zzso zzso cancer risk was lower in patients with multiple sclerosis than in the zzso zzso and calendar year matched general zzso The larger zzso sizes at cancer diagnosis suggested diagnostic zzso this could have major implications for the health, well-being and longevity of people with multiple zzso 

